Discovery of first steps in drug resistance process reveals new targets for antibiotics
Scientists have revealed the initial mechanisms that give rise to drug-resistant Escherichia coli, pointing to potential targets for antibiotics that remain effective as bacteria mutate. Read More
Wyss Institute, Boston Children’s Hospital, Northpond Labs to develop next-gen platform for compound screening
The Wyss Institute for Biologically Inspired Engineering at Harvard University said on Tuesday that it has entered into an agreement with Boston Children’s Hospital and Northpond Labs involving the development of an in vitro high-throughput platform that can identify compounds that bind target proteins with relevance to diseases. Read More
New insights into an old drug: Aspirin
Recent discoveries about how aspirin works to reduce inflammation could lead to alternative medications with fewer side effects. The National Institutes of Health (NIH)-funded research was presented on Tuesday at the annual meeting of the American Society for Biochemistry and Molecular Biology, held March 25-28 in Seattle. Read More
Thermo Fisher Scientific opens cell therapy facility at University of California, San Francisco
Thermo Fisher Scientific and the University of California, San Francisco (UCSF) said Monday that they will develop cell therapies for difficult-to-treat conditions, including cancers, rare diseases, and other illnesses. Read More
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
An analysis of 400 pancreatic cancer tumor samples has linked a protein that controls RNA processing to the formation of metastases, suggesting that it may be possible to delay the spread of the cancer. Read More
Clinical investigators need to be wary of confounding and bias in real-world studies; here is what to look for and how to address it
Clinical investigators use real-world data (RWD) in randomized trials and observational studies to produce real-world evidence (RWE) used to assess the safety and efficacy of an intervention and to inform product development, regulatory approval, and post-market surveillance efforts. Read More
HER2-targeting nanoparticles eradicate tumors in mice in ‘hit and run’ attack
A nanoparticle loaded with HER2-targeting antibody fragments and cytotoxic payloads performs a “hit and run” attack on gastric cancers in mice, eradicating the tumors while being safely cleared from the body via the kidneys to minimize toxicity. Read More
Simpler, cheaper screening method developed to democratize COVID-19 drug discovery
An alternative method for finding single-chain antibodies has yielded COVID-19 drug candidates that may be effective against variants of concern. Read More
Enzyme-activated drug candidate points to new way to treat liver cancer
Small molecules that are activated by an enzyme produced by some tumors could improve the treatment of liver cancer, a study run by scientists at the National Institutes of Health (NIH) and Massachusetts General Hospital suggests. Read More
GHIT Fund provides $1.9M for malaria drug development
The Global Health Innovative Technology (GHIT) Fund on Monday announced approximately $1.9 million (260 million yen) in funding for the research and development of a new malaria drug. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
